Sarepta's Duchenne Treatment Likely Making Progress At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Data in advisory committee briefing addendum judged major amendment, requiring more review time.
You may also be interested in...
US FDA Freezes Inspections And Outside Meetings. Will Review Goal Dates Stay Put?
Sponsors have been asked to switch to teleconferences with FDA staff as the agency prepares for more of its employees to work from home.
As Coronavirus Tightens Its Grip, US FDA Cancels Some Meetings Due To ‘Extenuating Circumstances’
Agency won't say whether patient-focused drug development meeting and gene therapy conference were postponed because of COVID-19, but other meetings remain as scheduled.
Sarepta Complained To Woodcock About Exondys 51 Review Early And Often
Documents also show that Sarepta officials begged CDER director for approval on multiple occasions prior to the agency's September 2016 decision.